Evaluation of the expression pattern of rAAV2/1, 2/5, 2/7, 2/8, and 2/9 serotypes with different promoters in the mouse visual cortex

This study compared the expression pattern, laminar distribution, and cell specificity of several rAAV serotypes (2/1, 2/5, 2/7, 2/8, and 2/9) injected in the primary visual cortex (V1) of adult C57Bl/6J mice. In order to obtain specific expression in certain neuron subtypes, different promoter sequences were evaluated for excitatory cell specificity: a universal cytomegalovirus (CMV) promoter, and two versions of the excitatory neuron‐specific Ca2+/calmodulin‐dependent kinase subunit α (CaMKIIα) promoter, CaMKIIα 0.4 and CaMKIIα 1.3. The spatial distribution as well as the cell type specificity was immunohistochemically verified. Depending on the rAAV serotype used, the transduced volume expressing reporter protein differed substantially (rAAV2/5 ≫ 2/7 ≈ 2/9 ≈ 2/8 ≫ 2/1). Excitatory neuron‐specific targeting was promoter‐dependent, with a surprising difference between the 1.3 kb and 0.4 kb CaMKIIα promoters. While CaMKIIα 1.3 and CMV carrying vectors were comparable, with 78% of the transduced neurons being excitatory for CMV and 82% for CaMKIIα 1.3, the shorter CaMKIIα 0.4 version resulted in 95% excitatory specificity. This study therefore puts forward the CaMKIIα 0.4 promoter as the best choice to target excitatory neurons with rAAVs. Together, these results can be used as an aid to select the most optimal vector system to deliver transgenes into specific rodent neocortical circuits, allowing further elucidation of their functions. J. Comp. Neurol. 523:2019–2042, 2015. © 2015 Wiley Periodicals, Inc.

[1]  T. Yamamori,et al.  Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex , 2015, Neuroscience Research.

[2]  S. Gray,et al.  Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. , 2015, Discovery medicine.

[3]  Michael J. Castle,et al.  Adeno-associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport. , 2014, Human gene therapy.

[4]  C. Vite,et al.  Adeno-associated virus serotypes 9 and rh10 mediate strong neuronal transduction of the dog brain , 2013, Gene Therapy.

[5]  Henning Scheich,et al.  Possible anatomical pathways for short-latency multisensory integration processes in primary sensory cortices , 2014, Brain Structure and Function.

[6]  R. Heilbronn,et al.  Differential Adeno-Associated Virus Serotype-Specific Interaction Patterns with Synthetic Heparins and Other Glycans , 2013, Journal of Virology.

[7]  S. Rumpel,et al.  Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain , 2013, PloS one.

[8]  J. Chiorini,et al.  Structural Insights into Adeno-Associated Virus Serotype 5 , 2013, Journal of Virology.

[9]  Marie-Eve Laramée,et al.  Cortical and subcortical projections to primary visual cortex in anophthalmic, enucleated and sighted mice , 2012, The European journal of neuroscience.

[10]  B. Byrne,et al.  Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9 , 2012, Journal of Virology.

[11]  Karl Deisseroth,et al.  Optogenetics in Neural Systems , 2011, Neuron.

[12]  J. Gale,et al.  Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum. Laboratory investigation. , 2011, Journal of neurosurgery.

[13]  J. Betley,et al.  Adeno-associated viral vectors for mapping, monitoring, and manipulating neural circuits. , 2011, Human gene therapy.

[14]  F. Coun,et al.  Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9 , 2011, Gene Therapy.

[15]  M. Agbandje-McKenna,et al.  AAV capsid structure and cell interactions. , 2011, Methods in molecular biology.

[16]  Bruce T. Lahn,et al.  Systematic Comparison of Constitutive Promoters and the Doxycycline-Inducible Promoter , 2010, PloS one.

[17]  R. Dahm,et al.  Transfection Techniques for Neuronal Cells , 2010, The Journal of Neuroscience.

[18]  Allan R. Jones,et al.  A robust and high-throughput Cre reporting and characterization system for the whole mouse brain , 2009, Nature Neuroscience.

[19]  M. During,et al.  Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  M. Passini,et al.  Long-term AAV vector gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters , 2009, Gene Therapy.

[21]  K. Obata,et al.  Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors , 2009, Neuroscience.

[22]  Nikolaus R. McFarland,et al.  Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system , 2009, Journal of neurochemistry.

[23]  Jacob G. Bernstein,et al.  Millisecond-Timescale Optical Control of Neural Dynamics in the Nonhuman Primate Brain , 2009, Neuron.

[24]  B. Davidson,et al.  Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. , 2008, Human gene therapy.

[25]  Brian L. Gilmore,et al.  Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi , 2008, Proceedings of the National Academy of Sciences.

[26]  M. Dichter,et al.  Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity , 2008, Brain Research.

[27]  R. Klein,et al.  AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  Quanxin Wang,et al.  Multiple Distinct Subtypes of GABAergic Neurons in Mouse Visual Cortex Identified by Triple Immunostaining , 2007, Frontiers in neuroanatomy.

[29]  Patrick R Hof,et al.  Neurofilament protein and neuronal activity markers define regional architectonic parcellation in the mouse visual cortex. , 2007, Cerebral cortex.

[30]  N. Muzyczka,et al.  Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 7. , 2007, Acta crystallographica. Section F, Structural biology and crystallization communications.

[31]  J. Wolfe,et al.  A Single Injection of an Adeno-Associated Virus Vector into Nuclei with Divergent Connections Results in Widespread Vector Distribution in the Brain and Global Correction of a Neurogenetic Disease , 2007, The Journal of Neuroscience.

[32]  B. Byrne,et al.  Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector , 2007, Journal of Virology.

[33]  R. Mandel,et al.  Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  Quanxin Wang,et al.  Area map of mouse visual cortex , 2007, The Journal of comparative neurology.

[35]  Zeger Debyser,et al.  Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. , 2007, Human gene therapy.

[36]  Edward B. Miller,et al.  Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1. , 2006, Acta crystallographica. Section F, Structural biology and crystallization communications.

[37]  P. Pivirotto,et al.  Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  M. Kay,et al.  The 37/67-Kilodalton Laminin Receptor Is a Receptor for Adeno-Associated Virus Serotypes 8, 2, 3, and 9 , 2006, Journal of Virology.

[39]  Edward B. Miller,et al.  α2,3 and α2,6 N-Linked Sialic Acids Facilitate Efficient Binding and Transduction by Adeno-Associated Virus Types 1 and 6 , 2006, Journal of Virology.

[40]  K. Jooss,et al.  Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors. , 2006, Human gene therapy.

[41]  Patrick R Hof,et al.  Variations in the structure of the prelunate gyrus in Old World monkeys. , 2006, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[42]  J. Bringas,et al.  Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. , 2006, Human gene therapy.

[43]  R. Mandel,et al.  Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  Shangzhen Zhou,et al.  Mutations on the External Surfaces of Adeno-AssociatedVirus Type 2 Capsids That Affect Transduction andNeutralization , 2006, Journal of Virology.

[45]  Edward B. Miller,et al.  Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. , 2006, Journal of virology.

[46]  J. Grieger,et al.  Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps , 2005, Journal of Virology.

[47]  James M. Wilson,et al.  New recombinant serotypes of AAV vectors. , 2005, Current gene therapy.

[48]  W. Denk,et al.  Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Samulski,et al.  Integration of adeno-associated virus (AAV) and recombinant AAV vectors. , 2004, Annual review of genetics.

[50]  P. Reier,et al.  Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  J. Feldon,et al.  Transduction Profiles of Recombinant Adeno-Associated Virus Vectors Derived from Serotypes 2 and 5 in the Nigrostriatal System of Rats , 2004, Journal of Virology.

[52]  T. Baker,et al.  Structure of Adeno-Associated Virus Serotype 5 , 2004, Journal of Virology.

[53]  E. Bamberg,et al.  Channelrhodopsin-2, a directly light-gated cation-selective membrane channel , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  B. Nuttin,et al.  Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain , 2003, Gene Therapy.

[55]  S. Kügler,et al.  Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. , 2003, Virology.

[56]  X. Breakefield,et al.  Viral vectors for gene delivery to the nervous system , 2003, Nature Reviews Neuroscience.

[57]  R W Guillery,et al.  The role of the thalamus in the flow of information to the cortex. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[58]  M. S. Chapman,et al.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. King,et al.  Dose and Promoter Effects of Adeno-Associated Viral Vector for Green Fluorescent Protein Expression in the Rat Brain , 2002, Experimental Neurology.

[60]  R. Samulski,et al.  Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity , 2002, Journal of Virology.

[61]  L. Arckens,et al.  Neurofilament protein: A selective marker for the architectonic parcellation of the visual cortex in adult cat brain , 2001, The Journal of comparative neurology.

[62]  J. Chiorini,et al.  Adeno-Associated Virus Serotype 4 (AAV4) and AAV5 Both Require Sialic Acid Binding for Hemagglutination and Efficient Transduction but Differ in Sialic Acid Linkage Specificity , 2001, Journal of Virology.

[63]  R. Samulski,et al.  Building a better vector: the manipulation of AAV virions. , 2000, Virology.

[64]  M. Emborg,et al.  Technique for Bilateral Intracranial Implantation of Cells in Monkeys Using an Automated Delivery System , 2000, Cell transplantation.

[65]  B. de Strooper,et al.  Gene therapeutic strategies for neurodegenerative diseases. , 2000, Current opinion in molecular therapeutics.

[66]  I. Martins,et al.  Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[67]  R. Samulski,et al.  Selective and rapid uptake of adeno-associated virus type 2 in brain. , 1998, Human gene therapy.

[68]  R. Samulski,et al.  Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.

[69]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[70]  J. DeFelipe,et al.  The pyramidal neuron of the cerebral cortex: Morphological and chemical characteristics of the synaptic inputs , 1992, Progress in Neurobiology.

[71]  E. White.  Cortical Circuits: Synaptic Organization of the Cerebral Cortex , 1989 .

[72]  Lingzhi Fan,et al.  The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system , 1988, Neuroscience Letters.

[73]  V. Caviness.  Architectonic map of neocortex of the normal mouse , 1975, The Journal of comparative neurology.